161 related articles for article (PubMed ID: 23138882)
21. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
22. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
Drake WM; Kendler DL; Brown JP
Clin Ther; 2001 Apr; 23(4):620-6. PubMed ID: 11354395
[TBL] [Abstract][Full Text] [Related]
23. Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Iizuka T; Matsukawa M
Climacteric; 2008 Aug; 11(4):287-95. PubMed ID: 18645694
[TBL] [Abstract][Full Text] [Related]
24. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.
Singer FR; Clemens TL; Eusebio RA; Bekker PJ
J Clin Endocrinol Metab; 1998 Jun; 83(6):1906-10. PubMed ID: 9626117
[TBL] [Abstract][Full Text] [Related]
25. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
26. [Paget's disease and its therapeutic management].
Orcel P; Rousière M
Presse Med; 2005 Apr; 34(8):612-6. PubMed ID: 15962504
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
[TBL] [Abstract][Full Text] [Related]
28. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
Siris E; Weinstein RS; Altman R; Conte JM; Favus M; Lombardi A; Lyles K; McIlwain H; Murphy WA; Reda C; Rude R; Seton M; Tiegs R; Thompson D; Tucci JR; Yates AJ; Zimering M
J Clin Endocrinol Metab; 1996 Mar; 81(3):961-7. PubMed ID: 8772558
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
Kishimoto H
Clin Calcium; 2008 Oct; 18(10):1417-26. PubMed ID: 18830038
[TBL] [Abstract][Full Text] [Related]
30. Changes in bone mineral density in patients with Paget's disease treated with risedronate.
Patel S; Pearson D; Bhallah A; Maslanka W; White DA; Hosking DJ
Ann Rheum Dis; 1997 Jul; 56(7):405-9. PubMed ID: 9486001
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
McClung MR; Miller PD; Brown JP; Zanchetta J; Bolognese MA; Benhamou CL; Balske A; Burgio DE; Sarley J; McCullough LK; Recker RR
Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
[TBL] [Abstract][Full Text] [Related]
32. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Krane SM
Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
[No Abstract] [Full Text] [Related]
33. Risedronate in Paget's disease: preliminary results of a multicenter study.
Brown JP; Kylstra JW; Bekker PJ; Axelrod DW; Siris ES; Altman RD; Singer FR
Semin Arthritis Rheum; 1994 Feb; 23(4):272. PubMed ID: 8009253
[No Abstract] [Full Text] [Related]
34. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
McClung MR; Balske A; Burgio DE; Wenderoth D; Recker RR
Osteoporos Int; 2013 Jan; 24(1):301-10. PubMed ID: 23079690
[TBL] [Abstract][Full Text] [Related]
35. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
Shiraki M; Fukunaga M; Kushida K; Kishimoto H; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H
Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates in the management of Paget's disease.
Ralston SH
Bone; 2020 Sep; 138():115465. PubMed ID: 32512166
[TBL] [Abstract][Full Text] [Related]
37. Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats.
Iwamoto J; Takeda T; Sato Y; Yeh JK
Exp Anim; 2007 Apr; 56(2):103-10. PubMed ID: 17460355
[TBL] [Abstract][Full Text] [Related]
38. Alternate calcitonin and etidronate disodium therapy for Paget's bone disease.
Perry HM; Droke DM; Avioli LV
Arch Intern Med; 1984 May; 144(5):929-33. PubMed ID: 6424594
[TBL] [Abstract][Full Text] [Related]
39. [Paget's disease of bone].
Takata S
Nihon Rinsho; 2006 Sep; 64(9):1724-30. PubMed ID: 16972687
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacological treatment of osteitis deformans (Paget's bone disease)].
Brixen KT; Abrahamsen B; Kassem MS; Mosekilde L
Ugeskr Laeger; 2005 Feb; 167(9):1009-12. PubMed ID: 15803994
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
